Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

B Cariou,L A Leiter,D Müller-Wieland, G Bigot,H M Colhoun,S Del Prato,R R Henry,F J Tinahones,A Letierce, L Aurand, J Maroni,K K Ray, M Bujas-Bobanovic

Diabetes & Metabolism（2017）

引用 17|浏览30

暂无评分

摘要

The ODYSSEY DM-INSULIN study will provide information on the efficacy and safety of alirocumab in insulin-treated individuals with T1 or T2 DM who are at high CV risk and have hypercholesterolaemia not adequately controlled by the maximum tolerated statin therapy.

查看译文

关键词

Alirocumab,Diabetes,Insulin,LDL-C,ODYSSEY,PCSK9

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要